UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K
___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): June 5, 2017

 

OWC P harmaceutical R esearch C orp.
(Exact Name of Registrant as Specified in its Charter)

 

Commission File No.: 0-54856

Delaware 98-0573566
(State of Incorporation) (I.R.S. Employer Identification No.)
    
30 Shacham Street. P.O.B. 8324 Petach Tikva, Israel 4918103
(Address of Principal Executive Offices) (ZIP Code)

Registrant's Telephone Number, including area code: 972 (0) 3-758-2657

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01. Other Events.

The Registrant has determined to evaluate the potential benefits of cross listing its shares of common stock, currently subject to quotation on the OTCQB: OWCP, for listing on a Canadian stock exchange, such as the Toronto Stock Exchange, among others. We believe that cross listing may improve the Registrant's access to capital and liquidity. To this end, the Registrant has agreed to engage a major national Canadian law firm with specific expertise in venture capital markets to assist us in achieving a listing on a Canadian exchange.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

OWC Pharmaceutical Research Corp.
     
By: /s/  Mordechai Bignitz  
Name: Mordechai Bignitz  
Title: Chief Executive Officer  

Date: June 7, 2017